Evidence map›Paper›PMID 26694720›Full record

ArticleHeart and vessels2016

Cardiovascular medicine heart failure (CVM-HF) index as prognostic model for candidates to MitraClip therapy.

Gian Paolo Ussia, Valeria Cammalleri, Ersilia Mazzotta, Giuseppina Pascuzzo, Saverio Muscoli, Massimo Marchei, Massimiliano Macrini, Andrea Anceschi, Francesco Romeo

Abstract read
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Functional status and quality of life after transcatheter mitral valve repair: a prospective cohort study and systematic review.Clinical research in cardiology : official journal of the German Cardiac Society · 2017
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gian Paolo UssiaDepartment of Cardiovascular Disease, Tor Vergata University of Rome, Viale Oxford, 81, 00133, Rome, Italy. gpussia@hotmail.com.
Valeria CammalleriDepartment of Cardiovascular Disease, Tor Vergata University of Rome, Viale Oxford, 81, 00133, Rome, Italy.
Ersilia MazzottaDepartment of Cardiovascular Disease, Tor Vergata University of Rome, Viale Oxford, 81, 00133, Rome, Italy.
Giuseppina PascuzzoDepartment of Cardiovascular Disease, Tor Vergata University of Rome, Viale Oxford, 81, 00133, Rome, Italy.
Saverio MuscoliDepartment of Cardiovascular Disease, Tor Vergata University of Rome, Viale Oxford, 81, 00133, Rome, Italy.
Massimo MarcheiDepartment of Cardiovascular Disease, Tor Vergata University of Rome, Viale Oxford, 81, 00133, Rome, Italy.
Massimiliano MacriniDepartment of Cardiovascular Disease, Tor Vergata University of Rome, Viale Oxford, 81, 00133, Rome, Italy.
Andrea AnceschiDepartment of Cardiovascular Disease, Tor Vergata University of Rome, Viale Oxford, 81, 00133, Rome, Italy.
Francesco RomeoDepartment of Cardiovascular Disease, Tor Vergata University of Rome, Viale Oxford, 81, 00133, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcatheter MitraClip repair is a new tool for the management of severe mitral regurgitation in patients at very high risk for conventional surgery. Aim of our study was reporting one-year clinical outcomes in candidates to MitraClip procedures, divided into three groups according to the cardiovascular medicine heart failure (CVM-HF) index. The study population consists of 46 consecutive patients, divided, in accordance with CVM-HF index, as follows: one patient in the low-risk category (group A); 27 patients in the medium-risk (group B) and 18 patients in high-risk category (group C). The primary study endpoint was a combined of all-cause mortality and re-hospitalization rate. Secondary endpoints were all-cause mortality and cardiac mortality. Patients of group B and group C were compared. Regarding the primary endpoint, patients in group C had significantly poorer outcomes than patients in group B, with a 12-month survival freedom from events of 44.4  and 74.1 %, respectively (log-rank test, p = 0.039); survival freedom from cardiac mortality was 100 and 83.3 % in group B and C, respectively (log-rank test, p = 0.027). One-year survival free from re-hospitalization was 74.1 % in group B and 39.9 % in group C (log-rank test; p = 0.036). Survival free from all-cause of mortality was 92.6 and 77.8 %, respectively (log-rank test; p = 0.129). In our initial experience the CVM-HF index showed to be valuable for understanding if the patient with advanced heart failure and functional mitral regurgitation can really benefit by MitraClip therapy.

Indexed as

AgedAged, 80 and overCardiac CatheterizationCause of DeathExercise TestFemaleFollow-Up StudiesHeart FailureHeart Valve Prosthesis ImplantationHumansKaplan-Meier EstimateMaleMiddle AgedMitral ValveMitral Valve InsufficiencyPatient ReadmissionHeart failureMitraClipMitral regurgitationPrognosis

Identifiers

PMID26694720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.